1. Volume 66, Issue 2, Pages 243-250 (August 2014)
Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial 
Thomas Wiegel, Detlef Bartkowiak, Dirk Bottke, Claudia Bronner, Ursula Steiner, Alessandra Siegmann, Reinhard Golz, Stephan Störkel, Normann Willich, Axel Semjonow, Michael Stöckle, Christian Rübe, Udo Rebmann, Tilman Kälble, Horst Jürgen Feldmann, Manfred Wirth, Rainer Hofmann, Rita Engenhart-Cabillic, Axel Hinke, Wolfgang Hinkelbein, Kurt Miller 
European Urology 
Volume 66, Issue 2, Pages (August 2014)
DOI: /j.eururo
Copyright © 2014 European Association of Urology Terms and Conditions

2. Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram.
HT=hormonal treatment; ITT=intent-to-treat; PSA=prostate-specific antigen.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier plot of progression-free survival after radical prostatectomy (RP) with and without adjuvant radiotherapy in intent-to-treat patients who achieved an undetectable prostate-specific antigen after RP (ITT2). Bottom: Patients at risk in the wait-and-see or adjuvant radiotherapy trial arm.
ART=adjuvant radiotherapy; PFS=progression-free survival; WS=wait-and-see.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions

4. Fig. 3
Forest plot for risk factors influencing the hazard ratio of progression-free survival in intent-to-treat patients who achieved an undetectable prostate-specific antigen after radical prostatectomy (ITT2) cohort with and without adjuvant radiotherapy.
CI=confidence interval; neg.=negative; PFS=progression-free survival; pos.=positive; PSA=prostate-specific antigen; RP=radical prostatectomy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions